Conduit Pharmaceuticals Inc.
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, whic… Read more
Conduit Pharmaceuticals Inc. (CDT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.194x
Based on the latest financial reports, Conduit Pharmaceuticals Inc. (CDT) has a cash flow conversion efficiency ratio of 0.194x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($245.00 Million) by net assets ($1.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Conduit Pharmaceuticals Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Conduit Pharmaceuticals Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Conduit Pharmaceuticals Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Conduit Pharmaceuticals Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
8PSB
XETRA:8PSB
|
N/A |
|
Tali Digital Ltd
AU:TD1
|
-0.218x |
|
Aspira Womens Health Inc
NASDAQ:AWH
|
0.398x |
|
Infinitum Copper Corp
OTCQB:INUMF
|
-0.250x |
|
Loyal Solutions AS
ST:LOYAL
|
0.017x |
|
AMNODE AB O.N.
F:Z9F0
|
N/A |
|
LafargeHolcim Ltd
MU:HLBN
|
N/A |
|
MX Gold Corp
PINK:MXLGF
|
0.000x |
Annual Cash Flow Conversion Efficiency for Conduit Pharmaceuticals Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Conduit Pharmaceuticals Inc. from 2021 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.26 Billion | $354.86 Million | 0.281x | -80.31% |
| 2024-12-31 | $-6.79 Million | $-9.68 Million | 1.425x | -91.57% |
| 2023-12-31 | $-457.00K | $-7.72 Million | 16.904x | +7426.11% |
| 2022-12-31 | $-10.09 Million | $-2.27 Million | 0.225x | +100.22% |
| 2021-12-31 | $20.62K | $-2.15 Million | -104.321x | -- |